In this issue:
- Is it time for rethinking major adverse cardiovascular events (MACE) as an endpoint in cardiovascular clinical trials? Yes, say trialists.
- Investigators find a small reduction in disabling stroke when using cerebral embolic protection devices during transcatheter aortic valve implantation (TAVI) procedures.
- A new course at the upcoming European Association for Cardio-Thoracic surgeons (EACTS) annual meeting (9–12 October: Lisbon, Portugal) will focus on training left-handed cardiac surgeons.
- PROFILE: ORBITA trial investigator Rasha Al-Lamee (London, UK) discusses her research.
- Updates on new structural heart technologies from EuroPCR 2024 (14–17 May; Paris, France) and New York Valves (5–7 June; New York, USA).
